Akero Therapeutics Stock Nearly Doubles — Pulling 89bio Higher — On Positive MASH Study
Akero Therapeutics Stock Nearly Doubles — Pulling 89bio Higher — On Positive MASH Study · Investor's Business Daily

In This Article:

Akero Therapeutics nearly doubled Monday — and pulled 89bio shares higher — after the company's treatment for MASH obliterated expectations.